Workenhe ST - Search Results

1

Viral-mediated activation and inhibition of programmed cell death.

Verburg SG, Lelievre RM, Westerveld MJ, Inkol JM, Sun YL, Workenhe ST. Verburg SG, et al. Among authors: workenhe st. PLoS Pathog. 2022 Aug 11;18(8):e1010718. doi: 10.1371/journal.ppat.1010718. eCollection 2022 Aug. PLoS Pathog. 2022. PMID: 35951530 Free PMC article. Review.

2

Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.

van Vloten JP, Workenhe ST, Wootton SK, Mossman KL, Bridle BW. van Vloten JP, et al. Among authors: workenhe st. J Immunol. 2018 Jan 15;200(2):450-458. doi: 10.4049/jimmunol.1701021. J Immunol. 2018. PMID: 29311387 Review.

3

Determinants for Antitumor and Protumor Effects of Programmed Cell Death.

Workenhe ST, Inkol JM, Westerveld MJ, Verburg SG, Worfolk SM, Walsh SR, Kallio KLF. Workenhe ST, et al. Cancer Immunol Res. 2024 Jan 3;12(1):7-16. doi: 10.1158/2326-6066.CIR-23-0321. Cancer Immunol Res. 2024. PMID: 37902605 Free PMC article.

4

Pyroptosis activates conventional type I dendritic cells to mediate the priming of highly functional anticancer T cells.

Inkol JM, Westerveld MJ, Verburg SG, Walsh SR, Morrison J, Mossman KL, Worfolk SM, Kallio KL, Phippen NJ, Burchett R, Wan Y, Bramson J, Workenhe ST. Inkol JM, et al. Among authors: workenhe st. J Immunother Cancer. 2024 Apr 4;12(4):e006781. doi: 10.1136/jitc-2023-006781. J Immunother Cancer. 2024. PMID: 38580330 Free PMC article.

5

Level of expression of MHCI-presented neoepitopes influences tumor rejection by neoantigen-specific CD8+ T cells.

Deng L, Walsh SR, Nguyen A, Inkol JM, Westerveld MJ, Chen L, El-Sayes N, Mossman KL, Workenhe ST, Wan Y. Deng L, et al. Among authors: workenhe st. Cancer Immunol Res. 2024 Oct 8. doi: 10.1158/2326-6066.CIR-23-0639. Online ahead of print. Cancer Immunol Res. 2024. PMID: 39377761

6

Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies.

Workenhe ST, Mossman KL. Workenhe ST, et al. Mol Ther. 2014 Feb;22(2):251-256. doi: 10.1038/mt.2013.220. Epub 2013 Oct 19. Mol Ther. 2014. PMID: 24048442 Free PMC article. Review.

7

Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning.

Pol JG, Atherton MJ, Stephenson KB, Bridle BW, Workenhe ST, Kazdhan N, McGray AR, Wan Y, Kroemer G, Lichty BD. Pol JG, et al. Among authors: workenhe st. J Immunother Cancer. 2020 Aug;8(2):e000981. doi: 10.1136/jitc-2020-000981. J Immunother Cancer. 2020. PMID: 32792361 Free PMC article.

8

De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors.

Workenhe ST, Nguyen A, Bakhshinyan D, Wei J, Hare DN, MacNeill KL, Wan Y, Oberst A, Bramson JL, Nasir JA, Vito A, El-Sayes N, Singh SK, McArthur AG, Mossman KL. Workenhe ST, et al. Commun Biol. 2020 Nov 4;3(1):645. doi: 10.1038/s42003-020-01362-w. Commun Biol. 2020. PMID: 33149194 Free PMC article.

9

Tumor-intrinsic determinants of immunogenic cell death modalities.

Workenhe ST, Pol J, Kroemer G. Workenhe ST, et al. Oncoimmunology. 2021 Mar 2;10(1):1893466. doi: 10.1080/2162402X.2021.1893466. Oncoimmunology. 2021. PMID: 33717656 Free PMC article. Review.

10

Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.

Workenhe ST, Simmons G, Pol JG, Lichty BD, Halford WP, Mossman KL. Workenhe ST, et al. Mol Ther. 2014 Jan;22(1):123-31. doi: 10.1038/mt.2013.238. Epub 2013 Oct 9. Mol Ther. 2014. PMID: 24343053 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34 results

Search Page

Filters